Prosensa

Prosensa used exon-skipping technology to develop drisapersen, an antisense oligonucleotide, for the treatment of Duchenne Muscular Dystrophy, a lethal childhood genetic disease that has no curative therapy. Prosensa went public in June 2013 and was acquired by BioMarin for up to $840 million in February 2015. Drisapersen did not, however, secure approval from the FDA.